Short Interest in Venus Concept Inc. (NASDAQ:VERO) Drops By 13.5%

Venus Concept Inc. (NASDAQ:VERO) was the target of a large decline in short interest during the month of January. As of January 15th, there was short interest totaling 172,610 shares, a decline of 13.5% from the December 31st total of 199,499 shares. Based on an average daily volume of 1,896,828 shares, the short-interest ratio is currently 0.1 days. Currently, 16.8% of the shares of the company are short sold. Currently, 16.8% of the shares of the company are short sold. Based on an average daily volume of 1,896,828 shares, the short-interest ratio is currently 0.1 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Venus Concept in a research note on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Venus Concept Trading Up 10.2%

NASDAQ VERO opened at $1.40 on Thursday. The stock has a market capitalization of $1.99 million, a P/E ratio of -0.03 and a beta of -0.01. Venus Concept has a 52-week low of $1.16 and a 52-week high of $14.50. The firm has a 50-day moving average price of $1.98 and a 200 day moving average price of $2.17. The company has a quick ratio of 0.59, a current ratio of 0.90 and a debt-to-equity ratio of 1.59.

Venus Concept (NASDAQ:VERO) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($12.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.61) by ($8.53). The business had revenue of $13.78 million during the quarter, compared to analysts’ expectations of $14.48 million. Venus Concept had a negative net margin of 92.76% and a negative return on equity of 1,904.25%.

Venus Concept Company Profile

Venus Concept Ltd. (NASDAQ: VERO) is a Canada-based medical aesthetic device company that designs, develops and commercializes minimally and noninvasive solutions for face and body rejuvenation. The company’s core product portfolio leverages proprietary technologies such as multi-polar radio frequency, pulsed electromagnetic fields and intense pulsed light to offer treatments for skin tightening, body contouring, wrinkle reduction and vascular lesion removal.

Among its flagship offerings are the Venus Legacy platform, which combines radio frequency and electromagnetic pulses for cellulite reduction and circumferential reduction, and the Venus Versa system, a multi-application device for facial revitalization, acne treatment, hair removal and photorejuvenation.